Month: <span>September 2019</span>

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study The collaboration will further explore the therapeutic potential of combination therapy, TJC4 with Keytruda across […]Read More

Biogen’s Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP’s

Shots: The CHMP recommended an update to MAA of approved interferon beta treatments (Plegridy & Avonex) to remove pregnancy contraindications and allow them to use during pregnancy and breastfeeding in women with relapsing multiple sclerosis The CHMP positive opinion is based on 1,000+ real-world pregnancy outcomes demonstrating no increased risk of major congenital anomalies after […]Read More

Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for

Shots: 3BP to receive $12M up front, R&D milestones, an additional potential milestone with royalties on sales. Clovis to get rights to develop peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha and will conduct global clinical studies excluding EU (inclusive of Russia, Turkey, and Israel) where 3BP retains rights Additionally, the […]Read More

AstraZeneca’s Qtrilmet Receives CHMP’s Recommendation for its Approval to Treat

Shots: The CHMP’s positive opinion is based on five P-III studies assessing Forxiga (dapagliflozin) + Onglyza (saxagliptin) + Metformin vs the Forxiga + Metformin/Onglyza + Metformin/Glimepiride/Metformin in patients with inadequately controlled T2D The P-III studies results demonstrated that Qtrilmet resulted in a reduction of HbA1c and is not inferior to the combined use of insulin […]Read More